236 related articles for article (PubMed ID: 35938916)
1. Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours.
Loughrey PB; Roncaroli F; Healy E; Weir P; Basetti M; Casey RT; Hunter SJ; Korbonits M
Endocr Relat Cancer; 2022 Oct; 29(10):R157-R172. PubMed ID: 35938916
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
[TBL] [Abstract][Full Text] [Related]
3. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.
Papathomas TG; Gaal J; Corssmit EP; Oudijk L; Korpershoek E; Heimdal K; Bayley JP; Morreau H; van Dooren M; Papaspyrou K; Schreiner T; Hansen T; Andresen PA; Restuccia DF; van Kessel I; van Leenders GJ; Kros JM; Looijenga LH; Hofland LJ; Mann W; van Nederveen FH; Mete O; Asa SL; de Krijger RR; Dinjens WN
Eur J Endocrinol; 2014 Jan; 170(1):1-12. PubMed ID: 24096523
[TBL] [Abstract][Full Text] [Related]
4. Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline
Santi R; Rapizzi E; Canu L; Ercolino T; Baroni G; Fucci R; Costa G; Mannelli M; Nesi G
Anticancer Res; 2017 Feb; 37(2):805-812. PubMed ID: 28179334
[TBL] [Abstract][Full Text] [Related]
5. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum.
Niemeijer ND; Papathomas TG; Korpershoek E; de Krijger RR; Oudijk L; Morreau H; Bayley JP; Hes FJ; Jansen JC; Dinjens WN; Corssmit EP
J Clin Endocrinol Metab; 2015 Oct; 100(10):E1386-93. PubMed ID: 26259135
[TBL] [Abstract][Full Text] [Related]
6. Germinal defects of SDHx genes in patients with isolated pituitary adenoma.
Mougel G; Lagarde A; Albarel F; Essamet W; Luigi P; Mouly C; Vialon M; Cuny T; Castinetti F; Saveanu A; Brue T; Barlier A; Romanet P
Eur J Endocrinol; 2020 Oct; 183(4):369-379. PubMed ID: 32621582
[TBL] [Abstract][Full Text] [Related]
7. A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma.
MacFarlane J; Seong KC; Bisambar C; Madhu B; Allinson K; Marker A; Warren A; Park SM; Giger O; Challis BG; Maher ER; Casey RT
Clin Endocrinol (Oxf); 2020 Nov; 93(5):528-538. PubMed ID: 32686200
[TBL] [Abstract][Full Text] [Related]
8. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
11. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.
Pasini B; Stratakis CA
J Intern Med; 2009 Jul; 266(1):19-42. PubMed ID: 19522823
[TBL] [Abstract][Full Text] [Related]
12. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
[TBL] [Abstract][Full Text] [Related]
13. Risk of metastatic pheochromocytoma and paraganglioma in
Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
[TBL] [Abstract][Full Text] [Related]
14. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
15. Back to Biochemistry: Evaluation for and Prognostic Significance of SDH Mutations in Paragangliomas and Pheochromocytomas.
Gupta S; Erickson LA
Surg Pathol Clin; 2023 Mar; 16(1):119-129. PubMed ID: 36739159
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
17. Models of parent-of-origin tumorigenesis in hereditary paraganglioma.
Hoekstra AS; Devilee P; Bayley JP
Semin Cell Dev Biol; 2015 Jul; 43():117-124. PubMed ID: 26067997
[TBL] [Abstract][Full Text] [Related]
18. SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?
Branzoli F; Salgues B; Marjańska M; Laloi-Michelin M; Herman P; Le Collen L; Delemer B; Riancho J; Kuhn E; Jublanc C; Burnichon N; Amar L; Favier J; Gimenez-Roqueplo AP; Buffet A; Lussey-Lepoutre C
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449569
[TBL] [Abstract][Full Text] [Related]
19. Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma.
Bayley JP; Bausch B; Rijken JA; van Hulsteijn LT; Jansen JC; Ascher D; Pires DEV; Hes FJ; Hensen EF; Corssmit EPM; Devilee P; Neumann HPH
J Med Genet; 2020 Feb; 57(2):96-103. PubMed ID: 31492822
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.
Castelblanco E; Santacana M; Valls J; de Cubas A; Cascón A; Robledo M; Matias-Guiu X
Endocr Pathol; 2013 Dec; 24(4):199-205. PubMed ID: 24096807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
